Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross‐sectional analysis from the <scp>MS‐STAT2</scp> randomized controlled trial
Date
2023-09Author
Subject
Metadata
Show full item recordAbstract
Background and purpose.There is increasing evidence that cardiovascular risk (CVR) contributes to disability progression in multiple sclerosis (MS). CVR is particularly prevalent in secondary progressive MS (SPMS) and can be quantified through validated composite CVR scores. The aim was to examine the cross‐sectional relationships between excess modifiable CVR, whole and regional brain atrophy on magnetic resonance imaging, and disability in patients with SPMS. Methods. Participants had SPMS, and data were collected at enrolment into the MS‐STAT2 trial. Composite CVR scores were calculated using the QRISK3 software. Prematurely achieved CVR due to modifiable risk factors was expressed as QRISK3 premature CVR, derived through reference to the normative QRISK3 dataset and expressed in years. Associations were determined with multiple linear regressions. Results. For the 218 participants, mean age was 54 years and median Expanded Disability Status Scale was 6.0. Each additional year of prematurely achieved CVR was associated with a 2.7 mL (beta coefficient; 95% confidence interval 0.8–4.7; p = 0.006) smaller normalized whole brain volume. The strongest relationship was seen for the cortical grey matter (beta coefficient 1.6 mL per year; 95% confidence interval 0.5–2.7; p = 0.003), and associations were also found with poorer verbal working memory performance. Body mass index demonstrated the strongest relationships with normalized brain volumes, whilst serum lipid ratios demonstrated strong relationships with verbal and visuospatial working memory performance. Conclusions. Prematurely achieved CVR is associated with lower normalized brain volumes in SPMS. Future longitudinal analyses of this clinical trial dataset will be important to determine whether CVR predicts future disease worsening.
Collections
Publisher
Place of Publication
Journal
Volume
Issue
Pagination
Author URL
Publisher URL
Recommended, similar items
The following license files are associated with this item:
Related items
Showing items related by title, author, creator and subject.
-
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Chataway, J; De Angelis, F; Connick, P; Parker, RA; Plantone, D; Doshi, A; John, N; Stutters, J; MacManus, D; Prados Carrasco, F; Barkhof, F; Ourselin, S; Braisher, M; Ross, M; Cranswick, G; Pavitt, SH; Giovannoni, G; Gandini Wheeler-Kingshott, CA; Hawkins, C; Sharrack, B; Bastow, R; Weir, CJ; Stallard, N; Chandran, S; Chataway, J; Gandini Wheeler-Kingshott, CAM; De Angelis, F; Plantone, D; Doshi, A; John, N; Williams, T; Braisher, M; Beyene, T; Bassan, V; Zapata, A; Chandran, S; Connick, P; Lyle, D; Cameron, J; Mollison, D; Colville, S; Dhillon, B; Weir, CJ; Parker, RA; Ross, M; Cranswick, G; Giovannoni, G; Gnanapavan, S; Nicholas, R; Rashid, W; Aram, J; Ford, H; Overell, J; Young, C; Arndt, H; Duddy, M; Guadagno, J; Evangelou, N; Craner, M; Palace, J; Hobart, J; Sharrack, B; Paling, D; Hawkins, C; Kalra, S; McLean, B; Stallard, N; Bastow, R (Elsevier BVEngland, 2020-03)BACKGROUND: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs ... -
Prevalence and associated clinical characteristics of walking-related motor, and cognitive, fatigability in progressive multiple sclerosis: baseline results from the CogEx study
Freeman, J (SageUnited States, 2024-03-01)Abstract Background: People with progressive multiple sclerosis (PMS) present motor (eg, walking) and cognitive impairments, and report fatigue. Fatigue encompasses fatigability which is objectively measured by the capacity ... -
Standing up in multiple sclerosis (SUMS): protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis.
Freeman, JA; Hendrie, W; Creanor, S; Jarrett, L; Barton, A; Green, C; Marsden, J; Rogers, E; Zajicek, J (Springer Science and Business Media LLCEngland, 2016-05-05)Multiple sclerosis (MS) is an incurable, unpredictable but typically progressive neurological condition. It is the most common cause of neurological disability in young adults. Within 15 years of diagnosis, approximately ...